Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Sales and Divestitures: 2018-2023

  • Dianthus Therapeutics' Gains from Sales and Divestitures fell 91.51% to $6,495 in Q4 2023 from the same period last year, while for Dec 2023 it was $6,495, marking a year-over-year decrease of 91.51%. This contributed to the annual value of $6,495 for FY2023, which is 91.51% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $6,495 for Q4 2023, which was down 0.00% from $6,495 recorded in Q3 2023.
  • Over the past 5 years, Dianthus Therapeutics' Gains from Sales and Divestitures peaked at $76,539 during Q4 2022, and registered a low of $6,495 during Q3 2023.
  • Over the past 2 years, Dianthus Therapeutics' median Gains from Sales and Divestitures value was $6,495 (recorded in 2023), while the average stood at $29,843.
  • Data for Dianthus Therapeutics' Gains from Sales and Divestitures shows a maximum YoY slumped of 91.51% (in 2023) over the last 5 years.
  • Over the past 2 years, Dianthus Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $76,539 in 2022, then slumped by 91.51% to $6,495 in 2023.
  • Its Gains from Sales and Divestitures was $6,495 in Q4 2023, compared to $6,495 in Q3 2023 and $76,539 in Q4 2022.